Market Outlook Shifts
Jyotivardhan Jaipuria, Founder and Managing Director of Valentis Advisors, signals a potential turnaround for Indian equities. He notes that while tariff-linked stocks face headwinds amid fading trade deal hopes, the broader market may find footing from improving corporate earnings and a deceleration in foreign capital outflows. Jaipuria expects this year to outperform last year for the stock market.
Earnings Revival
A key driver for optimism is the anticipated earnings recovery. After several quarters of sluggish single-digit growth, Jaipuria foresees the potential for double-digit earnings expansion across companies in the coming quarters. This projected earnings momentum is seen as a crucial support for stock valuations.
Foreign Investor Flows
Foreign institutional investors (FIIs) are also expected to play a more supportive role. Jaipuria suggests that FII selling may lessen as the year progresses. India's underperformance relative to the MSCI Emerging Markets Index last year, coupled with valuations returning to long-term averages, could encourage FIIs to re-engage, potentially turning them into buyers later in the year.
Sectoral Bets
Within specific sectors, metals are highlighted for their potential over the next 12 to 18 months. Despite inherent volatility, recent safeguard duties on hot-rolled coils are seen as a protective measure for domestic producers, suggesting this is an area where investors can profit. Protectionist policies could bolster the sector.
Technology Caution
Conversely, Jaipuria advises caution on information technology stocks, including major players like Tata Consultancy Services (TCS) and Infosys. He does not foresee a strong rebound, citing persistent structural challenges linked to artificial intelligence. These issues could suppress growth for several years, leading Valentis Advisors to maintain an underweight stance on the IT sector, viewing any buying opportunities as tactical rather than long-term investments.
Selective Opportunities
The chemicals and pharmaceuticals sectors present selective investment avenues. While the broader chemical industry grapples with competition from China, stock-specific catalysts like new capacity additions or export advantages could drive performance. Pharmaceutical stocks, which have experienced a prolonged period of underperformance, may now offer value as market pessimism appears to be fully priced in.